For the quarter ending 2025-09-30, CYTK made $1,936,000 in revenue. -$305,986,000 in net income. Net profit margin of -15805.06%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenues | 1,936,000 | 66,769,000 | 1,579,000 | 4,845,666.667 |
| Research and development | 99,233,000 | 112,554,000 | 99,841,000 | 84,932,000 |
| General and administrative | 69,458,000 | 65,721,000 | 57,369,000 | 52,887,333.333 |
| Total operating expenses | 168,691,000 | 178,275,000 | 157,210,000 | 137,819,333.333 |
| Operating loss | -166,755,000 | -111,506,000 | -155,631,000 | -131,815,666.667 |
| Interest expense | 11,353,000 | 11,084,000 | - | 9,591,000 |
| Non-cash interest expense on liabilities related to revenue participation right purchase agreements | 14,969,000 | 13,181,000 | 14,078,000 | 11,813,666.667 |
| Interest and other expense, net | - | - | 8,868,000 | - |
| Interest and other income, net | 10,248,000 | 13,001,000 | 13,701,000 | 11,493,333.333 |
| Change in fair value of derivative liabilities | 700,000 | 3,000,000 | -400,000 | 200,000 |
| Change in fair value of liabilities related to rpi transactions | -2,800,000 | -14,600,000 | 3,900,000 | -1,466,666.667 |
| Debt conversion expense | 121,249,000 | - | - | - |
| Net loss | -306,178,000 | -134,370,000 | -161,376,000 | -142,993,666.667 |
| Unrealized gain (loss) on available-for-sale securities, net | 167,000 | -851,000 | -541,000 | -1,460,666.667 |
| Foreign currency translation adjustments | 25,000 | -852,000 | -312,000 | 127,000 |
| Comprehensive loss | -305,986,000 | -136,073,000 | -162,229,000 | -144,327,333.333 |
| Earnings per share, basic, total | -2.55 | -1.12 | -1.36 | -1.3 |
| Earnings per share, diluted, total | -2.55 | -1.12 | -1.36 | -1.3 |
| Weighted average number of shares outstanding, basic, total | 119,982 | 119,457 | 118,496 | -1,902 |
| Weighted average number of shares outstanding, diluted, total | 119,982 | 119,457 | 118,496 | -1,902 |
CYTOKINETICS INC (CYTK)
CYTOKINETICS INC (CYTK)